Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499835 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT02499835 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 66 participants.
The verdict
NCT02499835, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL pTVG-HP Plasmid DNA Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499835
The ClinicalTrials.gov registry entry for NCT02499835 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02499835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499835 about?
NCT02499835 is a clinical study titled "Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer". This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-H...
What is the current status of trial NCT02499835?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2015-07-01. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT02499835?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), pTVG-HP Plasmid DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02499835?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.